Evonik has posted 2013 net income of EUR2.1bn (US$2.9bn) and group sales of EUR12.9bn in what it describes as “difficult market conditions.”
The net income rose 76% to EUR2.1bn due to divestment gains from real estate activities, while adjusted EBITDA was EUR2bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“We have achieved our strategic objectives: Evonik is now a publicly listed speciality chemicals company,” said Evonik chairman, Klaus Engel.
“Operationally, we achieved solid results in difficult market conditions.”
For 2014 Evonik says it expects sales to rise slightly, with adjusted EBITDA estimated to be between EUR1.8bn and EUR2.1bn.
“Evonik is now listed on the stock exchange and since last summer’s divestment of the majority of shares in the real estate activities, a well-positioned and focused speciality chemicals company,” said Engel.
“In 2013 we made considerable progress with our growth strategy: The first major projects in our investment programme were completed.”
